MR Image Synthesis With Low Gadobutrol Dose and AI
Summary
Study 22403 is a Phase 1 / Proof of Concept exploratory investigation to assess the non-inferiority of low dose gadobutrol and SubtleGAD™, a software medical device using an Artificial Intelligence (AI) deep learning-based method to enhance the contrast signal from images acquired with low dose administration of gadobutrol (GAD) contrast. The primary objective is to demonstrate noninferiority of synthesized Central Nervous System (CNS) magnetic resonance (MR) images for 1 or 2 different gadobutrol-enhanced low-dose groups (0.01mmol/kg, and0.025 mmol/kg) compared to gadobutrol-enhanced CNS MR images at a standard dose of 0.1 mmol/kg. This investigation is a prospective, randomized, open label, multi-center study with blinded reads in participants with known or highly suspected CNS pathology. There will be at least 60 participants enrolled (30 per study arm). SubtleGAD will be used as a post-processing tool, prior to blinded read assessment of MR images acquired in either arm of the study.
Timeline
- Start
- 2023-06-16
- Primary completion
- 2025-07-07
- Completion
- 2025-08-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Gadobutrol | Diagnostic / imaging agent | 0.01 mmol | Intravenous |
| Comparator | Gadobutrol | Diagnostic / imaging agent | 0.025 mmol | Intravenous |
| Comparator | Gadobutrol | Diagnostic / imaging agent | 0.1 mmol | Intravenous |
Indications
No indication recorded.